Benzinga - On CNBC’s "Halftime Report Final Trades," Brenda Vingiello of Sand Hill Global Advisors named Abbott Laboratories (NYSE: ABT) as her final trade.
On Monday, Raymond James maintained Abbott Laboratories with an Outperform and lowered the price target from $123 to $116, while BTIG maintained the stock with a Buy and raised the price target from $125 to $130.
Benzinga's analyst rating data finds a consensus Buy rating on ABT.
Jenny Harrington of Gilman Hill Asset Management said National Retail Properties, Inc. (NYSE: NNN) has a 5% dividend yield.
The company’s Board of Directors recently declared a quarterly dividend of 55 cents per share.
Don’t forget to check out our premarket coverage here
Stephen Weiss of Short Hills Capital Partners named UnitedHealth Group Incorporated (NYSE: UNH), which reported better-than-expected Q1 results and increased 2023 guidance.
Joseph Terranova of Virtus Investment Partners picked JPMorgan Chase & Co. (NYSE: JPM), which reported stronger-than-expected results for its first quarter, on Friday.
Price Action: Abbott Laboratories shares rose 0.5% to close at $104.52, while National Retail Properties gained 2% to settle at $43.40 on Monday. UnitedHealth fell 1.3% to $505.35, while JPMorgan rose 0.8% to $139.83 on Monday.
Check This Out: Top 5 Health Care Stocks That May Fall Off A Cliff This Quarter
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.